| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 12777670 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 764 journal articles in the PubMed database | Email to a friend | | |
| Suleiman M, Gruberg L, Hammerman H, et al.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. [Journal Article]
J Invasive Cardiol 2003 Jun; 15(6):319-23.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | |
Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Am Heart J 2001 Mar; 141(3):402-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Coons JC, Seybert AL, Saul MI, et al.
Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. [Journal Article]
Ann Pharmacother 2005 Oct; 39(10):1621-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Schweiger MJ, Changezi HU, Naglieri-Prescod D, et al.
Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. [Clinical Trial, Journal Article]
Clin Ther 2003 Jan; 25(1):225-34.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Merlini PA, Rossi M, Menozzi A, et al.
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Circulation 2004 May 11; 109(18):2203-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ajani AE, Waksman R, Gruberg L, et al.
Acute procedural complications and in-hospital events after percutaneous coronary interventions: eptifibatide versus abciximab. [Journal Article]
Cardiovasc Radiat Med 2003 Jan-Mar; 4(1):12-7.
Abstract | Full Citation | Find Related Articles | | Fahdi IE, Saucedo JF, Hennebry T, et al.
Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. [Journal Article]
Am J Cardiol 2004 Feb 15; 93(4):453-5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Gurm HS, Smith DE, Collins JS, et al.
The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. [Comparative Study, Journal Article]
J Am Coll Cardiol 2008 Feb 5; 51(5):529-35.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kimmelstiel C, Phang R, Rehman A, et al.
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. [Journal Article]
J Thromb Thrombolysis 2001 May; 11(3):203-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
